logo
  • Home
  • Technologies
    • Live Cell Encapsulation
    • Research & Development
    • Cancer
    • Diabetes
    • Cannabinoids
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
    • International Diabetes Consortium
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Dec 11, 2018

PharmaCyte Discusses Pancreatic Cancer Clinical Trial with Medpace’s Medical Monitor Dr. Lyon Gleich

  • Dec 4, 2018

PharmaCyte Biotech Engages cGMP Validation to Assist in Preparation of IND for Pancreatic Cancer Trial

  • Nov 15, 2018

PharmaCyte Biotech Completes Report of FDA Required Study Assessing Safety of Placement of Its Pancreatic Cancer Product

  • Nov 6, 2018

PharmaCyte Biotech Selects Medpace as CRO for Its Clinical Trial in Pancreatic Cancer

  • Oct 30, 2018

PharmaCyte Biotech Announces Publication of United States Patent Application for Cancer Therapies

  • Oct 9, 2018

PharmaCyte Biotech Announces Publication of PCT Patent Application for Cancer Therapies

  • Oct 1, 2018

PharmaCyte Biotech Reports Completion of Crucial FDA-Required Study for Pancreatic Cancer Trial

  • Sep 27, 2018

PharmaCyte Biotech Successfully Completes Comparative Analysis of Methods for Measuring Viability of Encapsulated Cells

  • Sep 18, 2018

PharmaCyte Biotech Successfully Completes Final Pre-Production Run of Pancreatic Cancer Product

  • Jul 23, 2018

PharmaCyte Biotech Successfully Completes Another Study on the Encapsulated Cells Used in Its Pancreatic Cancer Therapy

RSS
  • 1
  • 2
  • 3
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites May 23, 2022
  • PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes April 27, 2022